At the recent Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM), researchers from the Nestlé Health Science Ltd. and collaborators presented preclinical efficacy data on CDX-6114, an oral phenylalanine ammonia lyase in a model of phenylketonuria (PKU).
CDX-6114 shows efficacy in large-animal PKU model
